Department of Infectious Disease, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China (mainland).
Child Health Care Center, Changsha Hospital for Maternal and Child Health Care, Changsha, Hunan, China (mainland).
Med Sci Monit. 2018 Oct 24;24:7586-7594. doi: 10.12659/MSM.910844.
BACKGROUND Lysine-specific demethylase 5B (KDM5B) is overexpressed in several types of cancer. However, the clinical significance of KDM5B expression in hepatocellular carcinoma (HCC) remains unclear. The aims of the present study were to examine the functional effects of KDM5B in the Hep3B cell line, the expression levels of KDM5B in human HCC tissues, and the association between KDM5B expression and clinical outcome in patients with HCC. MATERIAL AND METHODS Immunohistochemistry (IHC) and quantitative real-time polymerase chain reaction (qRT-PCR) were used to examine the expression levels of KDM5B in HCC tissues and adjacent normal liver tissues. In the HCC cell line, Hep3B, the effects of KDM5B on cell proliferation and migration, and KDM5B small interfering RNA (siRNA) were used to study KDM5B knockdown. Univariate and multivariate analysis assessed the prognostic role of KDM5B in HCC patients. Kaplan-Meier analysis and the log-rank test evaluated clinical outcomes. RESULTS In the HCC cell line, Hep3B, KDM5B expression promoted promote tumor cell proliferation and colony formation. Increased expression of KDM5B in HCC tissues, compared with adjacent normal liver tissues, and was associated with larger tumor size, advanced TNM stage, and reduced overall survival in patients with HCC. Multivariate analysis identified KDM5B expression as an independent prognostic factor. CONCLUSIONS Increased expression of KDM5B was significantly correlated with poorer prognosis in patients with patients with HCC, indicating the possible potential of KDM5B as a novel clinical biomarker and therapeutic target.
赖氨酸特异性脱甲基酶 5B（KDM5B）在多种类型的癌症中过表达。然而，KDM5B 在肝细胞癌（HCC）中的表达的临床意义尚不清楚。本研究旨在研究 KDM5B 在 Hep3B 细胞系中的功能作用、人 HCC 组织中 KDM5B 的表达水平，以及 KDM5B 表达与 HCC 患者临床结局之间的关系。
免疫组织化学（IHC）和实时定量聚合酶链反应（qRT-PCR）用于检测 HCC 组织和相邻正常肝组织中 KDM5B 的表达水平。在 HCC 细胞系 Hep3B 中，研究了 KDM5B 对细胞增殖和迁移的影响，并使用 KDM5B 小干扰 RNA（siRNA）研究了 KDM5B 的敲低。单变量和多变量分析评估了 KDM5B 在 HCC 患者中的预后作用。Kaplan-Meier 分析和对数秩检验评估了临床结局。
在 HCC 细胞系 Hep3B 中，KDM5B 的表达促进了肿瘤细胞的增殖和集落形成。与相邻正常肝组织相比，HCC 组织中 KDM5B 的表达增加，且与较大的肿瘤大小、较晚的 TNM 分期和 HCC 患者的总生存期降低相关。多变量分析确定 KDM5B 表达是独立的预后因素。
KDM5B 表达的增加与 HCC 患者的预后较差显著相关，表明 KDM5B 可能成为一种新的临床生物标志物和治疗靶点。
